BEAMSTART Logo

HomeNews

Gennova Biopharma partners with CEPI to develop mRNA Nipah vaccine

Business Standard LogoBusiness Standard2d ago

Gennova Biopharma partners with CEPI to develop mRNA Nipah vaccine - Business Standard

Quick Summary:

This partnership sets a new benchmark for the rapid development of mRNA vaccines while ensuring equitable access and strengthening global health security.

Gennova’s saRNA technology could not only help fight Nipah but also contribute to future pandemic preparedness, potentially enabling rapid responses within 100 days of identifying a new viral threat.

In August 2023, CEPI granted the company $3.6 million to optimise its saRNA technology for developing vaccines against unknown pathogenic threats, often referred to as Disease X.


More Pictures

Gennova Biopharma partners with CEPI to develop mRNA Nipah vaccine - Business Standard (Picture 1)

or

Article Details

Category: BusinessFinance

Markets:

Topics:

Source Website Secure: Yes (HTTPS)

News Sentiment: Neutral

Fact Checked: Legitimate

Article Type: News Report

Published On: 2025-03-31 @ 20:59:03 (2 days ago)

News Timezone: GMT +5:00

News Source URL: business-standard.com

Language: English

Article Length: 488 words

Reading Time: 3 minutes read

Sentences: 21 lines

Sentence Length: 24 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © Business Standard

News ID: 27484367

View Article Analysis

About Business Standard

Business Standard Logo

Main Topics: BusinessFinance

Official Website: business-standard.com

Update Frequency: 274 posts per day

Year Established: 1975

Headquarters: India

News Last Updated: 2 hours ago

Coverage Areas: India

Ownership: Independent Company

Publication Timezone: GMT +5:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #49

Publisher Details

Frequently Asked Questions

How long will it take to read this news story?

The story "Gennova Biopharma partners with CEPI to develop mRNA Nipah vaccine" has 488 words across 21 sentences, which will take approximately 3 - 5 minutes for the average person to read.

Which news outlet covered this story?

The story "Gennova Biopharma partners with CEPI to develop mRNA Nipah vaccine" was covered 2 days ago by Business Standard, a news publisher based in India.

How trustworthy is 'Business Standard' news outlet?

Business Standard is a fully independent (privately-owned) news outlet established in 1975 that covers mostly business and finance news.

The outlet is headquartered in India and publishes an average of 274 news stories per day.

It's most recent story was published 2 hours ago.

What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.
  • News ID: #27484367
  • URL: https://chronographically.beamstart.com/news/gennova-biopharma-partners-with-cepi-1743435942477

BEAMSTART

BEAMSTART is a global entrepreneurship community, serving as a catalyst for innovation and collaboration. With a mission to empower entrepreneurs, we offer exclusive deals with savings totaling over $1,000,000, curated news, events, and a vast investor database. Through our portal, we aim to foster a supportive ecosystem where like-minded individuals can connect and create opportunities for growth and success.

© Copyright 2025 BEAMSTART. All Rights Reserved.